Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release Tablets As Brand Name For Its Investigational Atypical Antipsychotic

... Janssen, L.P., a wholly owned subsidiary of Johnson & Johnson, announced that it has selected INVEGA(TM) as the brand name for paliperidone extended release tablets, the company's investigational oral atypical antipsychotic. The company is seeking approval from the U.S. Food and Drug Administration (FDA) to market INVEGA(TM) for the treatment of schizophrenia. [click link for full article] ...